LncRNA KIAA0087 suppresses the progression of osteosarcoma by mediating the SOCS1/JAK2/STAT3 signaling pathway

被引:10
|
作者
Gong, Haoli [1 ]
Tao, Ye [2 ]
Xiao, Sheng [1 ]
Li, Xin [1 ]
Fang, Ke [1 ]
Wen, Jie [1 ]
He, Pan [1 ]
Zeng, Ming [1 ]
机构
[1] Hunan Normal Univ, Dept Orthoped, Hunan Prov Peoples Hosp, Affiliated Hosp 1, Changsha 410005, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Dept Radiol, Changsha 410013, Hunan, Peoples R China
来源
EXPERIMENTAL AND MOLECULAR MEDICINE | 2023年 / 55卷 / 04期
关键词
CANCER; EPIDEMIOLOGY; INVASION; SOCS1;
D O I
10.1038/s12276-023-00972-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Long noncoding RNAs (lncRNAs), widely expressed in mammalian cells, play pivotal roles in osteosarcoma (OS) progression. Nevertheless, the detailed molecular mechanisms of lncRNA KIAA0087 in OS remain obscure. Here, the roles of KIAA0087 in OS tumorigenesis were investigated. KIAA0087 and miR-411-3p levels were detected by RT-qPCR. Malignant properties were assessed by CCK-8, colony formation, flow cytometry, wound healing, and transwell assays. SOCS1, EMT, and JAK2/STAT3 pathway-related protein levels were measured by western blotting. Direct binding between miR-411-3p and KIAA0087/SOCS1 was validated by a dual-luciferase reporter, RIP, and FISH assays. In vivo growth and lung metastasis were evaluated in nude mice. The expression levels of SOCS1, Ki-67, E-cadherin, and N-cadherin in tumor tissues were measured by immunohistochemical staining. Downregulation of KIAA0087 and SOCS1 and upregulation of miR-411-3p were found in OS tissues and cells. Low expression of KIAA0087 was associated with a poor survival rate. Forced expression of KIAA0087 or miR-411-3p inhibition repressed the growth, migration, invasion, EMT, and activation of the JAK2/STAT3 pathway and triggered apoptosis of OS cells. However, the opposite results were found with KIAA0087 knockdown or miR-411-3p overexpression. Mechanistic experiments indicated that KIAA0087 enhanced SOCS1 expression to inactivate the JAK2/STAT3 pathway by sponging miR-411-3p. Rescue experiments revealed that the antitumor effects of KIAA0087 overexpression or miR-411-3p suppression were counteracted by miR-411-3p mimics or SOCS1 inhibition, respectively. Finally, in vivo tumor growth and lung metastasis were inhibited in KIAA0087-overexpressing or miR-411-3p-inhibited OS cells. In summary, the downregulation of KIAA0087 promotes the growth, metastasis, and EMT of OS by targeting the miR-411-3p-mediated SOCS1/JAK2/STAT3 pathway. Cancer: How one long non-coding RNA suppresses bone tumors A detailed understanding of how one particular non-coding regulatory RNA molecule suppresses the growth of bone tumors could lead to new treatments for osteosarcoma, the most common form of bone tumor. Ming Zeng of Hunan Provincial People's Hospital in Changsha, China, and colleagues showed that elevated activity of a long non-coding RNA called KIAA0087 reduces the proliferation, migration, and invasiveness of osteosarcoma tumors, both in cell culture experiments and in mice. The authors detailed how KIAA0087 binds to a smaller regulatory RNA and prevents it from inhibiting the expression of the protein it regulates. That protein is then expressed and is free to inactivate a signaling pathway that normally enhances tumor growth. These mechanistic insights offer several potential points of intervention for drug developers to create new targeted anti-cancer agents.
引用
收藏
页码:831 / 843
页数:13
相关论文
共 50 条
  • [21] Piperlongumine inhibits the progression of osteosarcoma by downregulating the SOCS3/JAK2/STAT3 pathway via miR-30d-5p
    Hu, Yawei
    Luo, Xinle
    Zhou, Jianhua
    Chen, Shaochu
    Gong, Ming
    Deng, Yue
    Zhang, Hao
    LIFE SCIENCES, 2021, 277
  • [22] Sciellin promotes the development and progression of thyroid cancer through the JAK2/STAT3 signaling pathway
    Guo, Haohao
    Wang, Ziyang
    Yin, Keyu
    Ma, Runsheng
    Zhang, Yifei
    Yin, Fanxiang
    Li, Hongqiang
    Yin, Detao
    MOLECULAR CARCINOGENESIS, 2024, 63 (04) : 701 - 713
  • [23] Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells
    Xiong, Hua
    Du, Wan
    Zhang, Yan-Jie
    Hong, Jie
    Su, Wen-Yu
    Tang, Jie-Ting
    Wang, Ying-Chao
    Lu, Rong
    Fang, Jing-Yuan
    MOLECULAR CARCINOGENESIS, 2012, 51 (02) : 174 - 184
  • [24] LOXL1-AS1 inhibits JAK2 ubiquitination and promotes cholangiocarcinoma progression through JAK2/STAT3 signaling
    Shaobo Yu
    Xin Gao
    Sidi Liu
    Xiangjun Sha
    Siyuan Zhang
    Xinmiao Zhang
    Dongsheng Sun
    Xingming Jiang
    Cancer Gene Therapy, 2024, 31 : 552 - 561
  • [25] Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway
    Jia, Fei
    Liu, Yu
    Dou, Xinyu
    Du, Chuanchao
    Mao, Tianli
    Liu, Xiaoguang
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [26] LOXL1-AS1 inhibits JAK2 ubiquitination and promotes cholangiocarcinoma progression through JAK2/STAT3 signaling
    Yu, Shaobo
    Gao, Xin
    Liu, Sidi
    Sha, Xiangjun
    Zhang, Siyuan
    Zhang, Xinmiao
    Sun, Dongsheng
    Jiang, Xingming
    CANCER GENE THERAPY, 2024, 31 (04) : 552 - 561
  • [27] PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway
    Zhong Lei
    Huijie Duan
    Tengfei Zhao
    Yuxiang Zhang
    Guoqi Li
    Jiahong Meng
    Suzhan Zhang
    Weiqi Yan
    Cell Death & Disease, 9
  • [28] PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway
    Lei, Zhong
    Duan, Huijie
    Zhao, Tengfei
    Zhang, Yuxiang
    Li, Guoqi
    Meng, Jiahong
    Zhang, Suzhan
    Yan, Weiqi
    CELL DEATH & DISEASE, 2018, 9
  • [29] TIAM2 promotes proliferation and invasion of osteosarcoma cells by activating the JAK2/STAT3 signaling pathway
    Cheng, Shaohua
    Huang, Xinghan
    Guo, Weichun
    JOURNAL OF BONE ONCOLOGY, 2022, 37
  • [30] Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signaling
    Zhang, Tao
    Li, Suoyuan
    Li, Jingjie
    Yin, Fei
    Hua, Yingqi
    Wang, Zhuoying
    Wang, Hongsheng
    Zuo, Dongqing
    Xu, Jing
    Cai, Zhengdong
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 153